BioSpace News Archive

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.

Garmin Health hits key milestone with completion of 500th research study.

JJP Biologics, a company that specializes in the development of proprietary biologic agents for personalized medicine approaches, has announced that the European Commission has approved the company’s application for designation of its product candidate JJP-1212 as an orphan medicinal product for treatment of Linear IgA Bullous Dermatosis (LABD).

Palatin Technologies, Inc. today announced that the first patient has been enrolled in the PL8177-205 study with Palatin’s PL8177, an oral formulation of the melanocortin-1 receptor agonist (MC1r), in patients with ulcerative colitis.

Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TELIGEN™ System.

Gibraltar Industries, Inc. announced today that it expects to release its third quarter 2022 financial results at approximately 7:30 a.m. ET on Thursday, November 3, 2022.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its third quarter 2022 financial results before the market opens on Thursday, November 3rd, 2022.

ImpediMed Limited (ASX: IPD) is pleased to announce publication of results from the PREVENT trial showing that early detection and intervention of breast cancer-related lymphedema reduces the burden of chronic lymphedema on patients.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the fourth annual Cancer Community Awards (C2 Awards).